Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Other Working Capital Changes (2016 - 2025)

Aptevo Therapeutics' Other Working Capital Changes history spans 11 years, with the latest figure at -$83000.0 for Q3 2025.

  • For Q3 2025, Other Working Capital Changes fell 111.13% year-over-year to -$83000.0; the TTM value through Sep 2025 reached -$670000.0, down 376.86%, while the annual FY2024 figure was -$217000.0, 41.83% down from the prior year.
  • Other Working Capital Changes for Q3 2025 was -$83000.0 at Aptevo Therapeutics, down from $203000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.4 million in Q3 2021 and bottomed at -$1.5 million in Q2 2023.
  • The 5-year median for Other Working Capital Changes is -$296000.0 (2022), against an average of -$79894.7.
  • The largest annual shift saw Other Working Capital Changes soared 384.12% in 2023 before it crashed 314.38% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$475000.0 in 2021, then soared by 157.89% to $275000.0 in 2022, then crashed by 46.91% to $146000.0 in 2023, then tumbled by 314.38% to -$313000.0 in 2024, then surged by 73.48% to -$83000.0 in 2025.
  • Per Business Quant, the three most recent readings for APVO's Other Working Capital Changes are -$83000.0 (Q3 2025), $203000.0 (Q2 2025), and -$477000.0 (Q1 2025).